



CONTACT



Kadıköy, Istanbul, Turkey

+90 (533) 581 63 81

mertcetiner30@gmail.com

linkedin.com/in/mertcetiner

mertcetiner.com

Driving Licence: B Class

CORE COMPETENCIES

- ICH-GCP
- Clinical Trial Management
- Site Coordination
- Patient Recruitment & Retention
- Regulatory Documentation
- Ethics Committee Submissions
- TITCK Processes
- AE / SAE Reporting
- Medidata Rave
- EDC Systems
- Query Resolution
- Monitoring Visit Support
- Source Documentation Review
- Sponsor & CRO Communication
- Protocol Compliance

LANGUAGES

Turkish: Native

English: Professional Working Proficiency

EDUCATION

Üsküdar University

B.Sc. Molecular Biology and Genetics

2018 – 2022

REFERENCE

Prof. Dr. MUSTAFA ÖZGÜROĞLU
Principal Investigator

Bilge Berberoğlu
Senior Site Manager

Özge Can Gümüş
Clinical Research Associate

MERT ÇETİNER

CLINICAL RESEARCH COORDINATOR

PROFESSIONAL SUMMARY

Clinical Research Coordinator with 3 years of oncology clinical trial experience at Cerrahpaşa Medical Faculty in collaboration with mediSMART CRO. Experienced in Phase I–III clinical studies, patient management, regulatory documentation, ethics committee submissions, SAE/AE reporting, EDC systems, monitoring visit preparation and sponsor communications. Worked with global sponsors including Johnson & Johnson (Janssen), Regeneron and AstraZeneca. Seeking to transition into a CRA role and contribute to high-quality clinical research operations.

PROFESSIONAL EXPERIENCE

JULY 2023-PRESENT

Clinical Research Coordinator | mediSMART CRO – Cerrahpaşa Medical Faculty | Jul 2023 – Present

• Coordinate 7 active oncology clinical trials across Phase I–III studies

• Manage approximately 25 clinical trial participants throughout screening, enrollment and follow-up

• Perform SAE/AE reporting and maintain safety documentation

• Prepare and submit Ethics Committee and TITCK regulatory documentation

• Manage EDC systems including Medidata Rave and sponsor-specific platforms

• Support monitoring visits, audits, inspections and site initiation activities

• Review source documentation and protocol compliance

• Collaborate with Principal Investigators, sponsors, CROs and study teams

• Support feasibility assessments, study start-up and patient recruitment activities

CLINICAL TRIAL PORTFOLIO

• Advanced Urothelial Carcinoma (Phase III)

• Advanced / Metastatic Non-Small Cell Lung Cancer (Phase III)

• EGFR-Mutated Non-Small Cell Lung Cancer (Phase III)

• HRR Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (Phase III)

• PD-L1 ≥50% Advanced Non-Small Cell Lung Cancer (Phase II/III)

• Resectable Early Stage Non-Small Cell Lung Cancer (Phase II)

• Metastatic Castration-Resistant Prostate Cancer (Phase III)